AmpC beta-lactamase in an Escherichia coli clinical isolate confers resistance to expanded-spectrum cephalosporins

Antimicrob Agents Chemother. 2004 Oct;48(10):4050-3. doi: 10.1128/AAC.48.10.4050-4053.2004.

Abstract

Cloning, sequencing, and biochemical analysis identified a novel AmpC-type beta-lactamase conferring resistance to extended-spectrum cephalosporins in an Escherichia coli clinical isolate. This enzyme, exhibiting 14 amino acid substitutions compared to a reference AmpC cephalosporinase of E. coli, hydrolyzed ceftazidime and cefepime significantly.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Amino Acid Sequence
  • Amino Acid Substitution
  • Bacterial Proteins / genetics
  • Bacterial Proteins / metabolism*
  • Cefepime
  • Ceftazidime / pharmacology
  • Cephalosporin Resistance / genetics*
  • Cephalosporins / pharmacology
  • Cloning, Molecular
  • DNA, Bacterial / genetics
  • Escherichia coli / drug effects
  • Escherichia coli / enzymology*
  • Escherichia coli / genetics
  • Escherichia coli Infections / microbiology*
  • Female
  • Humans
  • Kinetics
  • Molecular Sequence Data
  • beta-Lactamases / genetics
  • beta-Lactamases / metabolism*

Substances

  • Bacterial Proteins
  • Cephalosporins
  • DNA, Bacterial
  • Cefepime
  • Ceftazidime
  • AmpC beta-lactamases
  • beta-Lactamases

Associated data

  • GENBANK/AY533244
  • GENBANK/AY533245